Datasheet for ABIN2749022

anti-TRAIL antibody (AA 95-281)

2 Images | 1 Publication

Go to Product page

Overview

Quantity:	0.1 mg
Target:	TRAIL (TNFSF10)
Binding Specificity:	AA 95-281
Reactivity:	Human
Host:	Mouse
Clonality:	Monoclonal
Conjugate:	This TRAIL antibody is un-conjugated
Application:	Flow Cytometry (FACS), Functional Studies (Func)

Product Details

Immunogen:	Recombinant soluble fragment (aa 95-281) of human TRAIL.
Clone:	2E5
Isotype:	IgG1
Specificity:	The antibody 2E5 reacts with an extracellular epitope within C-terminal half of TRAIL (APO-2L), a 21 kDa cytotoxic protein, activator of rapid apoptosis in tumor cells. TRAIL is mainly expressed in spleen, lung, prostate and also in many other tissues.
No Cross-Reactivity:	Mouse
Cross-Reactivity (Details):	Human
Purification:	Purified by protein-A affinity chromatography.
Purity:	> 95 % (by SDS-PAGE)

Product Details

Endotoxin Level:	Endotoxin level is less than 0.01 EU/µg of the protein, as determined by the LAL test.

Target Details

Target:	TRAIL (TNFSF10)
Alternative Name:	CD253 / TRAIL (TNFSF10 Products)
Background:	TNF superfamily member 10,Human CD253 / TRAIL (TNF-related apoptosis inducing ligand), also called Apo2, is a type II membrane protein from the TNF family. TRAIL is a cytotoxic protein which activates rapid apoptosis in tumor cells, but not in normal cells. TRAIL-induced apotosis, is achieved through binding to two dealth-signaling receptors, DR4 (CD261 / TRAIL-R1) and DR5 (CD262 / TRAIL-R2).,TRAIL, Apo-2 ligand, Apo-2L, TNFSF10, APO2L, TNLG6A
Gene ID:	8743
UniProt:	P50591
Pathways:	Apoptosis, Positive Regulation of Endopeptidase Activity

Application Details

Application Notes:	Functional application: The antibody 2E5 has high neutralizing activity for human TRAIL in biological assays. Flow cytometry: Recommended dilution: 1-10 µg/mL.
Restrictions:	For Research Use only

Handling

Concentration:	1 mg/mL
Buffer:	Phosphate buffered saline (PBS), pH 7.4
Preservative:	Azide free
Storage:	4 °C
Storage Comment:	Store at 2-8°C. Do not freeze.

Publications

Product cited in:	Plasilova, Zivny, Jelinek, Neuwirtova, Cermak, Necas, Andera, Stopka: "TRAIL (Apo2L) suppresses growth of primary human leukemia and myelodysplasia progenitors." in: **Leukemia**, Vol. 16, Issue 1, pp. 67-73, (2002) (PubMed).

Images



Functional Studies

Image 1. Functional applicvation example: Apoptosis induced in JURKAT human T cell leukemia cell line by soluble recombinant human TRAIL is completely blocked by anti-human TRAIL (2E5). The neutralizing activity of the antibody 2E5 has been confirmed with various sources of soluble recombinant human TRAIL. A - medium B - recombinant TRAIL C - recombinant TRAIL + anti-human TRAIL (2E5, 0.06 µg/mL) D - recombinant TRAIL + anti-human TRAIL (2E5, 0.24 µg/mL) E - recombinant TRAIL + Isotype mouse IgG1 control



Apoptosis Detection

Image 2. Induction of apoptosis Apoptosis induced in JURKAT human T cell leukemia cell line by soluble recombinant human TRAIL is completely blocked by anti-human TRAIL (2E5). The neutralizing activity of the antibody 2E5 has been confirmed with various sources of soluble recombinant human TRAIL. A - medium B - recombinant TRAIL C - recombinant TRAIL + anti-human TRAIL (2E5; 0.06 µg/ml) D - recombinant TRAIL + anti-human TRAIL (2E5; 0.24 µg/ml) E - recombinant TRAIL + Isotype mouse IgG1 control

